From the Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey.
Exp Clin Transplant. 2024 Jun;22(6):471-474. doi: 10.6002/ect.2023.0252.
Everolimus is an orally administered mechanistic target of rapamycin inhibitor in solid-organ transplant patients. In addition to the common adverse side effects of this treatment, such as hyperlipidemia, rash, stomatitis, anorexia, diarrhea, anemia, thrombocytopenia, and leukopenia, pulmonary toxicity is also an important adverse side effect. Although pulmonary toxicity due to everolimus has been reported mostly as pneumonitis, cases of pleural effusion due to everolimus have also been reported rarely. Chylothorax is defined as the accumulation of lymphatic fluid in the pleural space. It may develop secondary to trauma or malignancy. In this case report, we present a patient with chylothorax after everolimus treatment.
依维莫司是一种口服的雷帕霉素靶蛋白抑制剂，适用于实体器官移植患者。除了这种治疗常见的不良反应，如高血脂、皮疹、口炎、厌食、腹泻、贫血、血小板减少和白细胞减少外，肺毒性也是一种重要的不良反应。虽然依维莫司引起的肺毒性多表现为肺炎，但也有罕见的依维莫司引起胸腔积液的报道。乳糜胸是指淋巴液在胸膜腔内积聚。它可能继发于创伤或恶性肿瘤。在本病例报告中，我们介绍了 1 例依维莫司治疗后发生乳糜胸的患者。
